The Journal of Immunology · 2014 · 50 citations · 33 references
Life SciencesImmunologyPharmacologyImmunopharmacologyImmunoregulationImmunotherapyB Cell BiologyB-cell ResponsesHumoral ImmunityImmunogenicity Of Therapeutic AntibodiesImmunoglobulin FunctionImmunomodulatory DrugsAntibody-mediated Immunity To BacteriaB Cell-mediated ImmunityB-cell Mediated ImmunityImmunoglobulin ResponsesJak Inhibitor TherapyJak Inhibitors
Immunogenicity remains the "Achilles' heel" of protein-based therapeutics. Anti-drug Abs produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding class of agent. In this article, we report that monotherapy of mice with tofacitinib (the JAK inhibitor) quells Ab responses to an immunotoxin derived from the bacterial protein Pseudomonas exotoxin A, as well as to the model Ag keyhole limpet hemocyanin. Thousand-fold reductions in IgG1 titers to both Ags were observed 21 d post immunization. In fact, suppression was evident for all IgG isotypes and IgM. A reduction in IgG3 production was also noted with a thymus-independent type II Ag. Mechanistic investigations revealed that tofacitinib treatment led to reduced numbers of CD127+ pro-B cells. Furthermore, we observed fewer germinal center B cells and the impaired formation of germinal centers of mice treated with tofacitinib. Because normal Ig levels were still present during tofacitinib treatment, this agent specifically reduced anti-drug Abs, thus preserving the potential efficacy of biological therapeutics, including those used as cancer therapeutics.
33
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text
Medicine, Immunology, Pharmacology +13
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text
Medicine, Immunology, Pharmacology +17
Defective Lymphoid Development in Mice Lacking Jak3
Tetsuya Nosaka, Jan M. A. van Deursen, Ralph A. Tripp et al. · Science · 1995 · 649 citations
Life Sciences, Genetics, Immunology +15
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi, Michael I. Jesson, Li Xiong et al. · The Journal of Immunology · 2011 · 644 citations · Full text